Pulmonary Hypertension in Patients with Moderate to Severe Hypersensitivity Pneumonitis Authors: Tjasa Kamenski-Rathmanner, Adrienn Tornyos, Luka Brcic, Emina Talakic, Helmut Prosch, Izidor Kern, Holger Flick, Grazyna Kwapiszewska, Alberto Benazzo, Horst Olschewski, Nikolaus Kneidinger, Philipp Douschan, Vasile Foris, Teresa John, Martin Trinker, Katarina Zeder, Gabor Kovacs Published: 2026 ABSTRACT AbstractIntroductionHypersensitivity pneumonitis (HP) is characterized by a complex immunological reaction of the lung that may lead to chronic interstitial lung disease (ILD). Pulmonary hypertension (PH) may aggravate the clinical picture. We aimed to assess the prevalence of PH in 2 independent cohorts including patients with moderate and severe HP.MethodsWe retrospectively analyzed the data of HP patients with severe ILD undergoing lung transplantation (cohort-1) and invited HP patients with mild disease participating at pulmonary rehabilitation for a prospective screening for PH (cohort-2). The presence of PH was assessed by both echocardiography and right heart catheterization (RHC).ResultsIn cohort-1 (n = 55, median age 57 [95% CI 52–60] years, 59% male, forced vital capacity [FVC] 37 [35–45] %predicted), echocardiographic systolic pulmonary arterial pressure (sPAP) was available in 31 patients and showed elevated values (53 [45–63] mm Hg). Sixteen patients had a high probability of PH (sPAP >50 mm Hg). RHC was performed based on clinical suspicion of PH or as part of the clinical assessment for transplantation in 21 patients, revealing a mean pulmonary arterial pressure (mPAP) of 28 (24–33) mm Hg and a pulmonary vascular resistance (PVR) of 2.8 (2.2–3.4) Wood units in this group; PH was confirmed in 15 patients (71% of those undergoing RHC, 27% of the total cohort). In cohort-2 (n = 96, median age 62 [60–65] years, 66% male, FVC 98 [95–104] % predicted), echocardiographic screening was available in 88 patients and showed upper-normal sPAP values (29 [28–31] mm Hg). One (1%) patient had a high probability of PH. Following noninvasive clinical assessment, RHC was performed in 13 patients with suspected PH. Hemodynamic measurements showed an mPAP of 19 (16–21) mm Hg and a PVR of 1.9 (1.7–2.8) Wood units in this group, and PH was confirmed in 5 patients (38% of those undergoing RHC, 5% of the total cohort). All 5 patients had a plausible alternative explanation for their PH.ConclusionPH is a frequent complication in patients with HP and severe ILD. In HP patients with mild disease, PH is uncommon and alternative causes should be considered. Hypersensitivity pneumonitis (HP) is characterized by a complex immunological reaction of the lung in response to repetitive inhalation of a sensitizing allergen that may lead to interstitial lung disease (ILD) [1]. Based on registries and cohort studies, HP may represent about 4–13% of all ILDs, though reported proportions vary widely (2–47%) depending on diagnostic criteria, referral structures, and geographical region [1–3]. There are 2 subtypes of HP according to computed tomography (CT) findings–fibrotic and non-fibrotic HP. Differential diagnosis of HP is challenging, especially for the fibrotic subtype. A multidisciplinary board (MDB) approach is recommended, which should take exposure history, high resolution (HR)-CT and broncho-alveolar lavage (BAL) findings, and eventually lung tissue biopsy into account, in order to determine the likelihood of HP [1, 4]. Development of pulmonary hypertension (PH) in the context of ILD is a well-known complication of various ILDs, including HP [5]. According to recent studies, the presence of PH is associated with an up to fourfold increase in mortality in HP patients, especially in those with the fibrotic form of the disease [6, 7]. Therefore, early detection and appropriate management of PH in HP patients is crucial [2]. However, the variable combination of lung parenchymal and pulmonary vascular involvement in ILDs makes this patient population a difficult target to study and to manage clinically [7]. There are only limited data on the prevalence of PH among patients with HP, with varying study designs and diagnostic criteria: most studies estimating it between 28 and 44% [2, 6, 8–10]. However, to date there is no systematic epidemiological assessment of PH in HP patients that includes a standardized diagnostic approach and different disease severities of HP. The aim of this study was, therefore, to assess the prevalence and severity of PH in HP patients with a wide range of parenchymal involvement. Methods Study Population We included patients belonging to 2 different HP phenotypes in this study. In cohort-1, patients with severe HP-ILD were included, who underwent lung transplantation between 2011 und 2021 at the Medical University of Vienna for end-stage ILD. In addition to referral diagnoses, the diagnosis of HP was confirmed retrospectively by MDB involving pulmonologists, radiologists, and pathologists, in accordance with current ATS/JRS/ALAT guidelines [1], following the integration of clinical data, exposure history, HRCT pattern, BAL, and histology. HRCT patterns were categorized according to current guideline recommendations as typical, compatible, or indeterminate for HP [4]. In cohort-2, we included patients, who were diagnosed with HP and underwent pulmonary rehabilitation between December 1997 and June 2015 in Klinikum Bad Gleichenberg (Rehabilitation Clinic for Agricultural Workers in Austria). These patients were invited for prospective clinical follow-up investigations at the Medical University of Graz and their clinical data were collected. Data Collection and Procedures For patients in cohort-1, clinical data including age, sex, height, weight, detailed medical history, smoker status, pulmonary function test, echocardiography, right heart catheterization (RHC), 6-min walk distance, and BAL fluid results, as well as chest CT scan and histopathology with tissue samples were collected. For patients in cohort-2, we prospectively assessed clinical data including age, sex, height, weight, detailed medical history and smoker status. In addition, we performed pulmonary function tests, echocardiography, laboratory tests including N-terminal pro brain natriuretic peptide (NT-proBNP), 6-min walk test and cardio-pulmonary exercise testing (CPET). In cohort-2, due to ethical reasons, RHC was only performed in subjects with suspected PH, based on noninvasive assessment and current PH guidelines [11, 12]. The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee (EK 976/2010 Vienna (“Vienna Lungs”), EK 1417/2022 Vienna (“Vienna Lungs”), EK-Nr. 32-446 ex 19/20). Written informed consent was obtained from all participants prior to study inclusion. In most echocardiography reports of cohort-1, not the tricuspid regurgitation velocity, but the estimated systolic pulmonary arterial pressure (sPAP) has been provided. Therefore, we decided to use this parameter to define a high echocardiographic probability of PH, when the estimated sPAP was >50 mm Hg. According to the current ESC/ERS guidelines, PH was defined as mean pulmonary arterial pressure mPAP >20 mm Hg assessed by RHC and severe PH was defined by mPAP >20 mm Hg and pulmonary vascular resistance >5 WU [12]. Forced vital capacity (FVC) was available for most patients in both cohorts, while total lung capacity was frequently absent in cohort-1; therefore, FVC was used for correlation analyses. We adhered to the STROBE (Strengthening the reporting of observational studies in epidemiology) statement when reporting this data. Statistical Analysis Continuous variables are presented as median values and 95% confidence intervals (CIs), whereas categorical variables are shown as absolute counts and corresponding percentages. For continuous parameters, distributional assumptions were examined visually (Q-Q plots) and numerically (Shapiro-Wilk). In order to present our data in a unified manner, we decided to show median values and 95% CIs both for normally and non-normally distributed variables. Comparisons between cohort-1 and cohort-2 regarding demographic, functional, and hemodynamic variables were performed descriptively due to the observational nature of the study and the absence of predefined comparative hypotheses. Differences between cohort-1 and cohort-2 were assessed using the nonparametric Mann-Whitney U test, and p values are reported in Tables 1 and 2. To explore the relationship between pulmonary function and pulmonary hemodynamics, we assessed the association between FVC (%predicted) and echocardiographic sPAP across both cohorts. Given linearity of the relationship on scatter inspection, Pearson correlation coefficients were calculated. Associations were interpreted using standard thresholds (|r| ≥ 0.4 = moderate, |r| ≥ 0.6 = strong). Receiver operating characteristic (ROC) analysis was performed to determine the optimal FVC threshold for predicting a high echocardiographic probability of pulmonary hypertension defined as sPAP >50 mm Hg. The optimal cut-off value was determined using the Youden index. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for this threshold. All analyses were performed using IBM SPSS Statistics, Version 29 (IBM Corp., Armonk, NY, USA). A p value <0.05 was considered statistically significant. Table 1.Demographic data, pulmonary function test, 6-min walk distance (6MWD), peak oxygen uptake (Peak VO2) and N-terminal pro brain natriuretic peptide (NT-proBNP) of patients from cohort-1 and 2Demographic dataCohort-1, n = 55Cohort-2, n = 96 p valueAge, years57 (52–60)62 (60–65)<0.001Male (n (%))34 (59%)64 (66%)0.55Height (cm)172 (168–176)173 (170–176)0.99Weight (kg)73 (68–78)87 (74–82)0.031Time between diagnosis of HP to LuTX (years)9 (6–11)––Pulmonary function test n =Cohort-1 n =Cohort-2 p valueFVC (%pred)4437 (35–45)9498 (95–104)<0.001FEV1 (%pred)5243 (38–49)9493 (86–98)<0.001FEV1/FVC (%)2987 (83–90)9475 (74–77)<0.001TLC (%pred)3352 (46–56)94101 (96–105)<0.001DLCOcVA (%pred)744 (17–48)9188 (85–95)<0.0016MWD (m)––92431 (420–460)–Peak VO2 (%)––8778 (73–83)–NT-pro-BNP, pg/mL––9665 (48–85)–Values are median (95% CI). p values refer to comparisons between cohort 1 and cohort 2 using the Mann-Whitney U test.LuTX, lung transplantation; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; TLC, total lung capacity; DLCOcVA, diffusing capacity divided by the alveolar volume; %pred, % predicted. Demographic data, pulmonary function test, 6-min walk distance (6MWD), peak oxygen uptake (Peak VO2) and N-terminal pro brain natriuretic peptide (NT-proBNP) of patients from cohort-1 and 2 Values are median (95% CI). p values refer to comparisons between cohort 1 and cohort 2 using the Mann-Whitney U test. LuTX, lung transplantation; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; TLC, total lung capacity; DLCOcVA, diffusing capacity divided by the alveolar volume; %pred, % predicted. Table 2.Main hemodynamic values of patients from cohort-1 and 2 assessed by echocardiography and right heart catheterization​ n =Cohort-1 n = 55 n =Cohort-2 n = 96 p valueEchocardiography sPAP, mm Hg3153 (45–63)8829 (28–31)<0.001 TAPSE, mm1824 (20–26)8423 (21–24)0.94Right heart catheterization mPAP, mm Hg2128 (24–33)1319 (16–21)0.007 PAWP, mm Hg205.5 (5.0–9.5)126 (4–8.5)0.53 CO, L/min165.4 (4.7–5.9)135.8 (5.2–6.2)0.50 PVR (WU)172.8 (2.2–3.4)121.9 (1.7–2.8)0.046Values are median (95% CI). p values refer to comparisons between cohort 1 and cohort 2 using the Mann-Whitney U test.sPAP, systolic pulmonary artery pressure; TAPSE, Tricuspid Annular Plane Systolic Excursion; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; CO, cardiac output; PVR, pulmonary vascular resistance; WU, wood units. Main hemodynamic values of patients from cohort-1 and 2 assessed by echocardiography and right heart catheterization Values are median (95% CI). p values refer to comparisons between cohort 1 and cohort 2 using the Mann-Whitney U test. sPAP, systolic pulmonary artery pressure; TAPSE, Tricuspid Annular Plane Systolic Excursion; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; CO, cardiac output; PVR, pulmonary vascular resistance; WU, wood units. Results We included n = 55 patients in cohort-1 (Table 1). Pulmonary function test results revealed severe restriction and impaired diffusion capacity of the lung (DLCO) (Table 1). Echocardiographic estimation of sPAP was available in n = 31 patients and revealed elevated values in all patients (53 (45–63) mm Hg). Out of these patients, n = 16 (52%) had a high echocardiographic probability of PH (estimated sPAP >50 mm Hg). N = 21 patients underwent RHC before lung transplantation due to clinical reasons or as routine pretransplant procedure (Table 2) and out of them n = 15 had PH (71% of RHC, 27% of all patients). Of note, all patients had pre-capillary PH (no patient revealed PAWP >15 mm Hg) and n = 2 patients had severe PH. One of the patients in cohort-1 received PAH therapy prior to transplantation. We recruited n = 96 patients for cohort-2 (Table 1). Pulmonary function tests overall revealed normal to slightly reduced values. Echocardiography showed normal right ventricular function and sPAP values in the upper-normal range in most subjects (29 [28–31] mm Hg). Only 1 patient (1%) had a high echocardiographic probability of PH. 6MWT and CPET revealed near normal exercise capacity, and NT-proBNP values were normal or slightly elevated (Table 2). Based on noninvasive investigations, PH was suspected and RHC was performed in n = 13 cases. PH was confirmed in 5 patients (38% of RHC, 5% of all patients): n = 3 revealing pre-capillary and n = 2 “unclassified” PH (elevated mPAP, but normal PVR and PAWP). None of the patients had severe PH and all 5 patients had a likely alternative cause explaining PH (Table 3). Table 3.Individual demographic, functional and hemodynamic values of patients from cohort-2 with confirmed PH (pulmonary hypertension) (n = 5)Demographic data12345Age, years5881605678Male/female (m/f)mfmmfHeight, cm178164178178166Weight, kg72757682100Pulmonary function test FVC (%)52601366576 FEV1 (%)39481003276 FEV1/FVC (%)5866573982 TLC (%)917112211870 DLCOcVA (%)96122333984 WHO-FCIIIIIIIIIIIIII 6MWD, m406270420420168 Peak VO2 (%)83796038– NT-proBNP, pg/mL281,07935864946Hemodynamics sPAP, mm Hg4642594443 TAPSE, mm251429–31 mPAP, mm Hg2121253521 PAWP, mm Hg614689 CO, L/min5.153.625.515.766.11 PVR (WU)2.91.93.44.71.96Alternative clinical condition explaining PH​COPDHFpEF*CPFE**COPDHFpEF*CPFE, combined pulmonary fibrosis and emphysema; FVC, forced vital capacity, FEV1, forced expiratory volume in 1 s; TLC, total lung capacity; DLCOcVA, diffusing capacity divided by the alveolar volume; %pred, % predicted; WHO-FC, World Health Organization functional class; 6MWD, 6-min walk distance; Peak VO2, peak oxygen uptake; NT-proBNP, N-terminal pro brain natriuretic peptide; sPAP, systolic pulmonary artery pressure; TAPSE, Tricuspid Annular Plane Systolic Excursion; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; CO, cardiac output; PVR, pulmonary vascular resistance; WU, wood units.*With abnormal PAWP increase during exercise.**This patient presented both with fibrosis and emphysema in chest CT. Individual demographic, functional and hemodynamic values of patients from cohort-2 with confirmed PH (pulmonary hypertension) (n = 5) CPFE, combined pulmonary fibrosis and emphysema; FVC, forced vital capacity, FEV1, forced expiratory volume in 1 s; TLC, total lung capacity; DLCOcVA, diffusing capacity divided by the alveolar volume; %pred, % predicted; WHO-FC, World Health Organization functional class; 6MWD, 6-min walk distance; Peak VO2, peak oxygen uptake; NT-proBNP, N-terminal pro brain natriuretic peptide; sPAP, systolic pulmonary artery pressure; TAPSE, Tricuspid Annular Plane Systolic Excursion; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; CO, cardiac output; PVR, pulmonary vascular resistance; WU, wood units. *With abnormal PAWP increase during exercise. **This patient presented both with fibrosis and emphysema in chest CT. When we combined cohorts-1 and 2, we found a significant negative correlation between forced vital capacity (FVC) and echocardiographic sPAP (R = − 0.56, p < 0.001, Fig. 1). ROC analysis demonstrated good discriminative ability of FVC for detecting a high echocardiographic probability of PH (sPAP >50 mm Hg), with an area under the curve (AUC) of 0.88. The optimal FVC cut-off was 47% predicted. At this threshold, sensitivity was 92%, specificity 92%, positive predictive value (PPV) 60%, and negative predictive value (NPV) 99%. Correlation between sPAP and FVC values in patients undergoing echocardiography both from cohort-1 and 2. Similarly, in the patients with available RHC data, a significant negative correlation was observed between FVC and mPAP (R = −0.51, p = 0.003, Fig. 2). ROC analysis demonstrated moderate discriminative ability of FVC for detecting PH (mPAP >20 mm Hg), with an area under the curve (AUC) of 0.71. The optimal FVC cut-off was 59% predicted. At this threshold, sensitivity was 78%, specificity 71%, PPV 78%, and NPV 71%. Correlation between mPAP and FVC values in patients undergoing right heart catheterization both from cohort-1 and 2. Discussion In this study, we systematically examined the prevalence and characteristics of PH across 2 cohorts of patients with HP representing a broad spectrum of parenchymal lung involvement. Our findings demonstrate that the occurrence of PH in HP is dependent on disease severity. In patients with advanced HP and severe ILD undergoing lung transplantation (cohort-1), PH was frequent. In this cohort, 71% of patients undergoing RHC, representing 27% of all patients fulfilled the diagnostic criteria of PH. In contrast, the prevalence of PH in patients with mild HP (cohort-2) was low. In this cohort, only 38% of patients undergoing RHC, representing 5% of all patients revealed PH, and all these cases may have also been associated with alternative underlying conditions. Overall, these results based on 2 independent cohorts suggest that parenchymal disease burden is the main determinant of pulmonary vascular involvement in HP, which has implications for clinical management of HP patients. While previous investigations reported PH prevalence rates between 28 and 44% in HP [2, 6, 8–10], there are limited data on the presence of PH across different degrees of ILD severity. RHC-based studies in chronic or fibrotic HP demonstrated PH prevalence around 50%, often in association with significantly impaired lung function, reduced DLCO, and marked exertional desaturation [9]. Similarly, a large study of HP patients awaiting lung transplantation reported pre-capillary PH in 52% of subjects [7]. Other studies relied on echocardiography or mixed populations at varied altitudes, making it challenging to drive conclusions [8, 10, 13]. Our data refine these earlier observations by differentiating high-risk and low-risk populations. The large discrepancy in PH prevalence between our 2 cohorts underscores the importance of PH awareness in HP patients, particularly if severe ILD is present. This is supported by the finding that 2 among these patients fulfilled the criteria for severe PH in RHC and thus being potentially eligible for PAH therapy, based on current guideline recommendations. A key finding of our study is the significant negative correlation between FVC and echocardiographic sPAP (r = −0.56, p < 0.001) as well as FVC and mPAP (ρ = −0.51, p = 0.003) across both cohorts, confirming that reduced lung volumes – primarily reflecting significant ILD – are associated with elevated pulmonary pressures. This aligns with prior studies linking impaired lung volumes and diffusion capacity to PH in HP and other forms of ILD [2, 6, 14]. Importantly, our results suggest a clinically actionable threshold: the presence of PH was very rare in patients with an FVC >60% and such observed PH cases were explained by alternative causes to ILD. These findings support FVC as a simple and robust functional marker for estimating PH risk in HP. PH has significant functional and prognostic implications in HP. Previous studies have shown an about fourfold increase in mortality in HP patients with PH, particularly in fibrotic subtypes [2, 6, 9]. Early recognition is therefore essential. Our data suggest that PH should be actively considered in patients with HP who exhibit FVC <60% predicted, given the higher probability of PH in these subjects. These patients should undergo at least echocardiography and NT-proBNP testing and at suspected PH, they should be presented in PH centers with experience in the management of chronic lung diseases. Diagnosing PH may influence decisions in these patients regarding optimization of rehabilitation programs, monitoring frequency, potential initiation of PH therapy and consideration for earlier lung transplantation evaluation. In patients with mild HP and FVC ≥60%, PH was a rare finding in our study and was mainly associated with alternative conditions. Thus, in HP patients with preserved spirometry and in the absence of other PH risk factors, the probability of relevant PH appears to be low. Of note, while FVC represents a simple and widely available parameter, future studies should assess whether combining FVC with other established predictors, such as DLCO, exercise-induced desaturation, NT-proBNP, or multiparametric risk assessment tools, improves the identification of HP patients at risk for PH. External validation in independent cohorts is required before recommending routine clinical application of any of these parameters and thresholds, including the FVC <60% threshold. Our study has limitations. Precise data on antigen exposure and laboratory findings were missing in several patients of cohort-1, as these were not available in the transplantation database and were not provided by the referring centers. Pulmonary function testing was incomplete in a substantial proportion of patients, with predominantly FVC available, while TLC and RV measurements were not consistently obtained. As TRV measurements were not consistently available in all patients, we decided to use an estimated sPAP >50 mm Hg as a pragmatic surrogate for a high echocardiographic probability of PH. This approach does not fully correspond to the current guideline-recommended algorithm. Given the well-known unprecision of noninvasive prediction of PH, especially in patients with lung diseases, our echocardiographic findings should be interpreted in conjunction with the available invasive hemodynamic data. Further, RHC data were not available for all patients in cohort-1, and in cohort-2, due to ethical considerations, RHC was only performed when PH was clinically suspected. Accordingly, the observed frequency of PH in patients undergoing RHC might not reflect true prevalence estimates in cohort-1 and overestimates it in cohort-2. Of note, the selective use of RHC in patients with low clinical probability of PH reflects current clinical practice, where systematic catheterization of all patients with interstitial lung disease would neither be feasible nor ethically justified. As further limitation, our cohorts differed substantially with respect to disease severity, clinical setting, diagnostic work-up, and the likelihood of undergoing invasive hemodynamic assessment. Therefore, the observed associations between lung function impairment and pulmonary vascular involvement might partly reflect the marked separation between these 2 populations rather than a purely continuous biological relationship across the entire spectrum of HP. Finally, the study is limited by the relatively small sample size. Nevertheless, these limitations may be balanced by the elaborate work-up of clinical data, the prospective design of cohort-2, the thorough multidisciplinary evaluation of patients and the wide range of lung involvement of the included subjects. In conclusion, PH is a frequent complication in patients with HP and severe ILD. Lung function, particularly FVC, is a strong indicator of PH risk and might guide targeted screening. Recognition of pulmonary vascular involvement is crucial, as the presence of PH substantially affects functional status, prognosis and therapeutic decisions. In HP patients with mild disease, PH is uncommon and alternative causes should be considered. Statement of Ethics This study was performed in accordance with the Declaration of Helsinki. This human study was approved by Ethics Committee of the Medical University of Vienna (“Vienna Lungs”) – approval: EK 976/2010, EK 1417/2022 and by Ethics Committee of the Medical University of Graz for the protocol “Investigations of explanted lung specimens from clinically indicated lung operations” – approval: EK-Nr. 32-446 ex 19/20. All adult participants provided written informed consent to participate in this study. Conflict of Interest Statement T.K.-R., A.T., E.T., I.K., H.F., G.K.W., N.K., M. T., and A.B. declare no conflicts of interest related to the present work. L.B. received speaker fees and consultation fees from AstraZeneca, MSD, BMS, Merck, BeOne, Ipsen, Pfizer, Eli Lilly, Roche, Novartis, Janssen, and Daiichi-Sankyo, and travel support from Pfizer within the last 3 years, not directly associated with the submitted manuscript. H.P. received speaker honoraria from AstraZeneca, BMS, Boehringer Ingelheim, Bracco, Daiichi-Sankyo, Janssen, MSD, Novartis, Roche, Sanofi, Siemens Healthineers, and Takeda; advisory board fees from BMS, Boehringer Ingelheim, Janssen, MSD, Roche, and Sanofi; travel grants from Boehringer Ingelheim; and research support from Boehringer Ingelheim, AstraZeneca, Siemens Healthineers, the Christian Doppler Research Association, and the European Commission (EU4Health, Horizon Europe Health). H.O. received author and lecture fees from Forum Sanitas, Thieme, Springer, and Conventus; consultancy fees from Inhibikase, Liquidia, Menarini, MSD, Paul Weiss, and Pulmovant; and served as DSMB member for AstraZeneca and Liquidia. P.D. reports personal fees from Actelion, Janssen, Johnson & Johnson, MSD, Ferrer, GSK, and Chiesi, and nonfinancial support from Actelion, Janssen, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim, GSK, MSD, Novartis, Menarini, Ferrer, and Chiesi outside the submitted work. V.F. was supported by the Austrian Society of Pneumology, Max Kade Foundation, and TOPMed Fellowship. V.F. received travel support from Boehringer Ingelheim, Austrian Scientists and Scholars in North America, and the European Respiratory Society, as well as travel support and lecture fees from Chiesi and Janssen unrelated to the current work. T.J. reports personal fees and nonfinancial support from Janssen and AOP, non-financial support from Ferrer, MSD, and Boehringer Ingelheim, and personal fees from Roche, outside the submitted work. K.Z. received consultation fees from AstraZeneca and investigator-initiated research grants from United Therapeutics and the Cardiovascular Medical Research and Education Fund (CMREF), not directly related to the submitted manuscript. G.K. received speaker fees and consultation fees from MSD, Chiesi, Johnson & Johnson, Ferrer, Boehringer Ingelheim, AOP, Liquidia, United Therapeutics, and Gossamer; travel support from AOP, MSD, Ferrer, Johnson & Johnson, and Boehringer Ingelheim; and investigator-initiated research grants from ERS, MSD, Johnson & Johnson, and Boehringer Ingelheim within the last 3 years, not directly associated with the submitted manuscript. Funding Sources This research received no external funding. Author Contributions T.K.-R. and A.T. contributed equally to this work. T.K.-R. and A.T. contributed to study conception and design, data collection, data analysis, interpretation of results, and drafting of the manuscript. A.T. contributed to data collection, data analysis, interpretation of data, and critical revision of the manuscript. L.B., E.T., H.P., I.K., H.F., G.K.W., and A.B. contributed to data acquisition and interpretation of data. H.O., N.K., P.D., V.F., T.J., M.T., and K.Z. contributed to study support, interpretation of results, and critical revision of the manuscript. G.K. contributed to study conception and design, supervision of the study, interpretation of results, and critical revision of the manuscript. All authors reviewed and approved the final version of the manuscript.